Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;11(5):443-448.
doi: 10.5114/jcb.2019.88619. Epub 2019 Oct 30.

Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma

Andrea Vavassori  1 , Giulia Riva  1   2 , Stefano Durante  1   2 , Cristiana Fodor  1 , Stefania Comi  3 , Raffaella Cambria  3 , Federica Cattani  3 , Giuseppe Spadola  4 , Roberto Orecchia  5 , Barbara Alicja Jereczek-Fossa  1   2
Affiliations

Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma

Andrea Vavassori et al. J Contemp Brachytherapy. 2019 Oct.

Abstract

Purpose: To evaluate toxicity and clinical outcomes in patients with eyelid tumour treated with contact high-dose-rate brachytherapy (HDR-BT).

Material and methods: Between April 2010 and August 2017, 10 consecutive patients with tumour of the eyelid underwent contact HDR-BT and custom-made surface mould. Every applicator was manually built using conventional thermoplastic material and standard plastic catheters. The median dose prescribed was 42 Gy (range, 30-48) with a median dose per fraction of 3.5 Gy (range, 2-4.5). The dose was delivered in a median of 12 fractions (range, 10-17) over a median of 16 days. In all cases, an ocular shield was placed to reduce the dose to the eye. Acute and late toxicity was evaluated according to RTOG toxicity criteria.

Results: We analyzed data of 9 of 10 patients (one patient was excluded because he did not give consent for investigation). The median age was 68 years (range, 31-88). According to the TNM-UICC staging system, 4, 1 and 4 patients were stage IA, IB and IC, respectively. Basal cell and sebaceous gland carcinomas were reported in 5 and 2 patients, respectively; other histological types were non-Hodgkin lymphoma and plasmacytoma. After a median follow-up of 51 months (range, 16-90), there was no evidence of local or distant recurrence. The treatment was very well tolerated. Most commonly acute reactions consisted of low grade (G1-G2) conjunctivitis and skin erythema. Only one patient required a temporary interruption of the treatment due to acute G2 conjunctivitis and G3 lid erythema. Only one G2 late toxicity was reported (corneal ulceration), without resulting in functional impairment or blindness.

Conclusions: Our results suggest that contact HDR-BT with a customized applicator is safe, effective and offers very good local control and can be considered for the treatment of eyelid tumours.

Keywords: HDR; HDR-BT; brachytherapy; eyelid.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
Custom-made moulds for treatment of eyelid tumour
Fig. 2
Fig. 2
Plasmacytoma of the lower eyelid before (A) and 40 months after (B) HDR-BT. CT-based planning of HDR-BT treatment (C)
See this image and copyright information in PMC

References

    1. Petsuksiri J, Frank SJ, Garden AS, et al. Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer. 2008;112:111–118. - PubMed
    1. Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol. 2009;31:256–262. - PubMed
    1. Silverman N, Shinder R. What’s new in eyelid tumors. Asia Pac J Ophthalmol. 2017;6:143–152. - PubMed
    1. Saleh GM, Desai P, Collin JR, et al. Incidence of eyelid basal cell carcinoma in England: 2000-2010. Br J Ophthalmol. 2017;101:209–212. - PubMed
    1. Yu SS, Zhao Y, Zhao H, et al. A retrospective study of 2228 cases with eyelid tumors. Int J Ophthalmol. 2018;11:1835–1841. - PMC - PubMed